We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Advertisement
Product
Advertisement
Sino Biological Inc logo

Therapeutic Targets in CAR NK-Cell Therapy

Therapeutic Targets in CAR NK-Cell Therapy


Advertisement
Sino Biological Inc logo

Natural killer (NK) cells are immune cells capable of killing target cells and can be genetically modified to express chimeric antigen receptors (CARs). CAR NK-cell therapy is an innovative type of cancer immunotherapy for solid tumors and hematological malignancies.


Functionally, CAR-NK cells kill target cancer cells in a CAR-dependent manner. Compared to traditional CAR-T cells, CAR-NK cells and unmodified NK cells offer safety advantages. The limited lifespan of CAR-NK cells greatly lowers the risk of on-target/off-tumor toxicity to normal cells. Additionally, reduced risk for alloreactivity and Graft versus host disease (GvHD) allows CAR-NK cells to be generated from a variety of sources, including NK92 cells, peripheral blood mononuclear cells (PBMCs), umbilical cord blood (UCB), and induced pluripotent stem cells (iPSCs).


Sino Biological provides a variety of CAR-NK-related proteins and antibodies with superior quality.